Mizoribine

咪唑立宾

Report date: 2022/12/07 17:15:10
NME

Base Information

Drug NameMizoribine
Drug Alias Name咪唑利宾mizoribina咪唑立兵mizoribinummizoribine +[8] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors
TargetsInosine-5'-monophosphate dehydrogenase (IMPDH)
Therapy Area/IndicationsRejection of renal transplantationNephrotic SyndromeLupus Nephritis +[4] 
Global Approved IndicationsRejection of renal transplantationNephrotic SyndromeLupus Nephritis +[4] 
Approved Indications in ChinaRejection of renal transplantation
Original Approved Country/TerritoryJapan
Original Approved Date1984/03/01
Country/TerritorySouth KoreaMainland ChinaJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesJanssen Pharmaceuticals IncAsahi Kasei (China) Investment Co LtdNorth China Pharmaceutical Huasheng Co Ltd +[5] 
Inactive CompaniesAsahi Kasei Pharma America CorpChong Kun Dang Pharmaceutical Corp
Active IndicationsRejection of renal transplantationNephrotic SyndromeLupus Nephritis +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AX
Related LinksWikipediaKEGG